News coverage about SenesTech (NASDAQ:SNES) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SenesTech earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.5070125974651 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities research analysts have weighed in on SNES shares. Zacks Investment Research upgraded shares of SenesTech from a “sell” rating to a “hold” rating in a research note on Friday, September 8th. Craig Hallum set a $3.00 price target on SenesTech and gave the company a “buy” rating in a report on Wednesday, November 22nd.

Shares of SenesTech (SNES) traded up $0.01 during mid-day trading on Friday, hitting $0.66. The stock had a trading volume of 38,600 shares, compared to its average volume of 157,892. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.94 and a quick ratio of 2.67. SenesTech has a one year low of $0.62 and a one year high of $10.69.

SenesTech (NASDAQ:SNES) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. SenesTech had a negative return on equity of 190.41% and a negative net margin of 14,473.40%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.25 million.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at

About SenesTech

SenesTech, Inc is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes.

Insider Buying and Selling by Quarter for SenesTech (NASDAQ:SNES)

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with's FREE daily email newsletter.